My Crossword Maker Logo
Powered by BrightSprout
Save Status:
or to save your progress. The page will not refresh.
Controls:
SPACEBAR SWITCHES TYPING DIRECTION
Answer Key:
Edit a Copy:
Make Your Own:
Crossword Word Search Worksheet
Rate This Puzzle:
Log in or sign up to rate this puzzle.

The Cynical Scribe's Guide to the Top 20 US Oncology Labs - USCAP 2020 Edition

If you need extra clues, contact [email protected]
Across
We're #6. The Prophet Garcia sang "One man gathers what another man spills." We sang that song to GE and Novartis, who both bought high and sold low.
We're #5. We recently fired our CEO, and our quarterly reports could be country western songs - "My patents left me...then my growth left me."
We're #16. When we sold the lab to Konica Minolta, our founder accumulated the 2nd biggest family IVD fortune in the world (after Randox).
We're #18. We went public last summer. Oncologists are liking our clonoSEQ MRD panels.
We're #20, and the #1 oncology lab in greater Atlanta
We're #10 in overall oncology revenues, and we're also the #2 academic reference lab. The Pacific and Mountain time zones are our home court.
We're now #3 (until recently #2). Many Tarheels, Blue Devils, and Demon Deacons work here. Halloween is scary every year.
We're #12 overall and the #3 academic reference lab. We have America's biggest outpatient footprint. Rockefeller got his start down the street.
We're #15. We're Foundation's main competitor in the US. Some bigger lab will buy us this year or next year.
Down
G'Day Mate - We're #4 in the US, #2 in Europe, and #1 Down Under. Now that we've digested Aurora, expect us to buy an NGS lab pretty soon.
We're #11 - the apex predator of liquid biopsy markets.
We're #9. Drug companies drive by our lab and throw bags of cash at our door, then they drive off. So we don't much care what you pay us for clinical cases - whatever you got's OK.
We're the #1 academic reference lab. If you want to work here, you need to have polar-expedition-worthy winter gear.
We're #17 nationwide, and #1 in the SEC states. Our founder is the richest pathologist in the US.
We're #14 now; a few years ago we were #3. Our CEO sold the lab in an all stock deal to a drug company with a fairy tale.
We're #13. We get $3000/patient for our thyroid panels and we just bought Nanostring's clinical business.
We're the new #1. We've been turning stool into cash for years, and we just bought the biggest prognostic lab.
We're #19 - the Walmart of NGS testing.
We're #8. Caris loved us and left us. Then Miraca loved us and left us. Now this opportunistic PE fund is dancing with us, but we don't trust them.
We were #1 but now we're #2. We've been slow out of the gate with our NGS menu, so we recently bought Blueprint Genetics.